Banca de DEFESA: AMANDA KATIELLY JORDÃO PESSOA FELIX DA SILVA

DEVELOPMENT OF A NEW COMPLEX OF OXOVANADIUM(IV)-DIAMINOALCOHOL, FREE AND BIOCOMPATIBILIZED: SYNTHESIS, CHARACTERIZATION, EVALUATION OF ACUTE TOXICITY AND ACTIVITY AGAINST INSULIN RESISTANCE

diabetes mellitus, vanadium, levan, Zymomonas mobilis, aminoalcohol.

The vanadium (IV) complexes have demonstrated antidiabetic activity, due to the ability to decrease blood glucose levels, increase insulin sensitivity in adipose and skeletal muscle tissues, besides having antioxidant effects, decreasing ROS and hypolipidemic effects, reducing the levels of triglycerides and total cholesterol. This work aims to develop a new oxovanadium (IV) complex using as ligand the diaminoalcohol biocompatibilized with the exopolysaccharide matrix Levan, obtained from the microorganism Zymomonas mobilis strain ZAG-12. The oxovanadium (IV) complex with the diaminoalcohol, abbreviated as VHEEDA, was synthesized and characterized by electronic and infrared absorption spectroscopy, 1H, 13C and 51V nuclear magnetic resonance, EPR and thermogravimetric analysis. The results demonstrated the reproducibility in obtaining the levan and the complex. The VHEEDA complex showed no nephrotoxicity and hepatotoxicity in the acute toxicity assay in mice, being classified as category 4 according to OECD protocol 423. In dexamethasone-induced insulin resistance activity, VHEEDA (95%) + Levana (5%) compositions with doses of 50 mg/Kg and 25 mg/Kg, showed a 50% reduction in blood glucose, triglycerides and TyG after 7 days of treatment, with no significant difference with the normoglycemic group (p>0. 05) Therefore, the composition of vanadium complex biocompatibilized with levan demonstrated antidiabetic activity by attenuating glucocorticoid-induced insulin resistance.